@article{9a4d3604d4f9417880c0eaf3d35c78f4,
title = "Combination of plasma neurofilament light chain and mini-mental state examination score predicts progression from mild cognitive impairment to alzheimer's disease within 5 years",
abstract = "Background: Individuals with mild cognitive impairment (MCI) are at high risk of progression to Alzheimer's disease (AD) dementia, but some remain stable. There is a need to identify those at higher risk of progression to improve patient management and outcomes. Objective: To evaluate the trajectory of plasma neurofilament light chain (pNFL) prior to progression from MCI to AD dementia, the performance of pNFL, in combination with the Mini-Mental State Examination (MMSE), as a predictor of progression from MCI to AD dementia and to inform clinicians on the use of pNFL as a predictive biomarker. Methods: Participants (n=440) with MCI and longitudinal follow-up (mean=4.2 years) from the AD Neuroimaging Initiative dataset were included. pNFL as a marker for neurodegeneration and the MMSE as a cognitive measure were investigated as simple/practical predictors of progression. The risk of progressing from MCI to AD dementia associated with pNFL and MMSE scores was assessed using Cox and logistic regression models. Results: The current risk of progression to AD dementia was 37%higher in individuals with high pNFL (>56ng/L) compared to those with average pNFL (≤40ng/L). A combination of baseline pNFL and MMSE could differentiate those who progressed within 5 years (AUC=0.75) from stable individuals. Including change in MMSE over 6-12 months further improved the model (AUC=0.84). Conclusion: Our findings reveal that combining pNFL with a simple dementia screener (MMSE) can reliably predict whether a person with MCI is likely to progress to AD dementia within 5 years.",
keywords = "Alzheimer's disease, clinical progression, mild cognitive impairment, neurofilament, plasma biomarkers",
author = "Nicolas Darmanth{\'e} and Hossein Tabatabaei-Jafari and Nicolas Cherbuin",
note = "Funding Information: Data collection and sharing for this work was funded by the Alzheimer{\textquoteright}s Disease Neuroimag-ing Initiative (ADNI; National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer{\textquoteright}s Association; Alzheimer Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec, Inc.; Bristol-Myers Squibb Company; Eisai, Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novar-tis Pharmaceuticals Corporation; Pfizer, Inc.; Piramal Imaging; Servier; Synarc, Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer{\textquoteright}s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Publisher Copyright: {\textcopyright} 2021 - IOS Press. All rights reserved.",
year = "2021",
month = aug,
day = "3",
doi = "10.3233/JAD-210092",
language = "English",
volume = "82",
pages = "951--964",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",
}